<DOC>
	<DOCNO>NCT01085812</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy F2695 sustain release ( SR ) relative placebo prevention depression relapse patient major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Relapse-Prevention Study With F2695 SR Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Patients demonstrate improvement depressive symptom end initial 12-week open-label treatment period F2695 SR randomize continue F2695 SR switch placebo double-blind condition 24 week additional treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Men woman , 1865 year old Currently meet DSMIVTR criterion Major Depressive Disorder The patient 's current depressive episode must least 4 week duration Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control Patients history meeting DSMIVTR criterion : manic hypomanic episode schizophrenia psychotic disorder obsessivecompulsive disorder Patients consider suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>